(INDIANAPOLIS, INDIANA – June 4, 2019) – Beckman Coulter Life Sciences today announced its acquisition of Cytobank, a privately held, single cell data analysis, software as a service (SaaS) company based in Santa Clara, California.
Cytobank provides an industry-leading, cloud and machine learning-based software platform for multi-parametric single-cell data analysis, sharing and archiving. The platform accelerates research productivity by enabling efficient high-dimensional multi-omics data analysis, visualization and collaboration across multiple sites. The technology pairs naturally with Beckman Coulter Life Sciences’ CytoFLEX LX 21-color flow cytometer to meet the growing high-complexity workflow and data analysis needs of basic and clinical research scientists.
“We are excited to add Cytobank’s innovative software solutions and customer workflow-focused team to our flow cytometry business,” said Mario Koksch, Flow Cytometry Business Unit Vice President and General Manager, Beckman Coulter Life Sciences. “We can now provide more standardized, yet flexible high-end data analytics solutions to Pharma/Biopharma and leading Academic clinical research customers.”
“Cytobank looks forward to joining Beckman Coulter Life Sciences, and leveraging synergies to help us further develop and support our platform to serve leading scientists globally,” said David Craford, President & CEO, Cytobank.
Cytobank will transition into Beckman Coulter Life Sciences under the Danaher Life Sciences platform, which generated approximately $6.5 billion in revenue during 2018.
| Contact: | Chris Suttile, Global Marketing |
| m| 317-672-8028 | |
| e| csuttile@beckman.com |